Kura Oncology Inc. (NASDAQ:KURA) was up 6.7% during trading on Wednesday . The company traded as high as $4.95 and last traded at $4.43, with a volume of 835,984 shares trading hands. The stock had previously closed at $4.15.

A number of research analysts have recently weighed in on KURA shares. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Tuesday, March 22nd. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, June 21st.

The firm’s 50-day moving average price is $3.12 and its 200 day moving average price is $3.88. The stock’s market cap is $80.21 million.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.01. On average, equities research analysts anticipate that Kura Oncology Inc. will post ($1.70) EPS for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.